Literature DB >> 8897462

Mitochondrial involvement in schizophrenia and other functional psychoses.

S A Whatley1, D Curti, R M Marchbanks.   

Abstract

Gene expression has been studied in post-mortem frontal cortex samples from patients who had suffered from schizophrenia and depressive illness. mRNA was extracted and characterised by translation and separation of the products by 2D gel electrophoresis. Post-mortem artefacts and the agonal experience did not affect the size distribution or amount of specific translation products. Four expression products were specifically reduced in samples from schizophrenics compared with normals. The expression of six products was altered in affective disorder, one in common with schizophrenia, two the same as in schizophrenia but increased. cDNA libraries were produced from the mRNA samples and 5 clones present at abnormal levels in schizophrenia identified by differential screening, isolated and sequenced. All the sequences encode mitochondrial transcripts; four encode mitochondrial rRNA and one the amino acid sequence of cytochrome oxidase sub-unit II. Increased cytochrome oxidase transcripts were found in a further set of mRNA extracts from schizophrenic patients including two who had not received neuroleptic medication. The effects of neuroleptic administration as exemplified by alpha-flupenthixol compared with the ineffective beta-flupenthixol were studied in experimental animals. It was found that 13 out of 28 clones whose levels were altered were mitochondrial in origin including rRNA, COX I & II and the NADH-Q reductase. Those encoding respiratory enzymes were at abnormally low levels as a result of alpha-flupenthixol administration. Measurements of the enzymic activity of cytochrome c oxidase in post-mortem frontal cortex of schizophrenics did not indicate any differences in overall activity but there was a decreased sensitivity to azide that was abolished by neuroleptics. Studies on NADH-cytochrome c reductase showed that schizophrenics whether medicated or not had a reduced rotenone sensitive activity that was compensated for by increased rotenone insensitive activity. We conclude that changes in mitochondrial gene expression are involved in schizophrenia and probably other functional psychoses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8897462     DOI: 10.1007/bf02532409

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  30 in total

1.  Activities of citrate synthase, NAD+-linked and NADP+-linked isocitrate dehydrogenases, glutamate dehydrogenase, aspartate aminotransferase and alanine aminotransferase in nervous tissues from vertebrates and invertebrates.

Authors:  P H Sugden; E A Newsholme
Journal:  Biochem J       Date:  1975-07       Impact factor: 3.857

2.  Brain cytochrome oxidase in Alzheimer's disease.

Authors:  S J Kish; C Bergeron; A Rajput; S Dozic; F Mastrogiacomo; L J Chang; J M Wilson; L M DiStefano; J N Nobrega
Journal:  J Neurochem       Date:  1992-08       Impact factor: 5.372

3.  Exclusion of a schizophrenia susceptibility gene from the chromosome 5q11-q13 region: new data and a reanalysis of previous reports.

Authors:  P McGuffin; M Sargeant; G Hetti; S Tidmarsh; S Whatley; R M Marchbanks
Journal:  Am J Hum Genet       Date:  1990-09       Impact factor: 11.025

4.  A simplified method for the quantitative assay of small amounts of protein in biologic material.

Authors:  G R Schacterle; R L Pollack
Journal:  Anal Biochem       Date:  1973-02       Impact factor: 3.365

5.  The RNA processing enzyme RNase MRP is identical to the Th RNP and related to RNase P.

Authors:  H A Gold; J N Topper; D A Clayton; J Craft
Journal:  Science       Date:  1989-09-22       Impact factor: 47.728

6.  Sex differences in the familial transmission of schizophrenia.

Authors:  J M Goldstein; S V Faraone; W J Chen; G S Tolomiczencko; M T Tsuang
Journal:  Br J Psychiatry       Date:  1990-06       Impact factor: 9.319

7.  Changes in relative levels of specific brain mRNA species associated with schizophrenia and depression.

Authors:  C W Perrett; S A Whatley; I N Ferrier; R M Marchbanks
Journal:  Brain Res Mol Brain Res       Date:  1992-01

8.  Association between lupus psychosis and anti-ribosomal P protein antibodies.

Authors:  E Bonfa; S J Golombek; L D Kaufman; S Skelly; H Weissbach; N Brot; K B Elkon
Journal:  N Engl J Med       Date:  1987-07-30       Impact factor: 91.245

9.  Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects.

Authors:  D C Goff; D C Henderson; E Amico
Journal:  Am J Psychiatry       Date:  1992-09       Impact factor: 18.112

10.  Mechanism of the antipsychotic effect in the treatment of acute schizophrenia.

Authors:  E C Johnstone; T J Crow; C D Frith; M W Carney; J S Price
Journal:  Lancet       Date:  1978-04-22       Impact factor: 79.321

View more
  25 in total

1.  Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia.

Authors:  Frank A Middleton; Karoly Mirnics; Joseph N Pierri; David A Lewis; Pat Levitt
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

Review 2.  The genetics of Tourette syndrome.

Authors:  Hao Deng; Kai Gao; Joseph Jankovic
Journal:  Nat Rev Neurol       Date:  2012-03-13       Impact factor: 42.937

Review 3.  Genetic association studies of antioxidant pathway genes and schizophrenia.

Authors:  Kodavali V Chowdari; Mikhil N Bamne; Vishwajit L Nimgaonkar
Journal:  Antioxid Redox Signal       Date:  2010-11-01       Impact factor: 8.401

Review 4.  New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors.

Authors:  Michael Maes; Zdenĕk Fišar; Miguel Medina; Giovanni Scapagnini; Gabriel Nowak; Michael Berk
Journal:  Inflammopharmacology       Date:  2012-01-24       Impact factor: 4.473

Review 5.  Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease.

Authors:  L Holper; D Ben-Shachar; J J Mann
Journal:  Neuropsychopharmacology       Date:  2018-05-16       Impact factor: 7.853

Review 6.  A Review and Update on Tourette Syndrome: Where Is the Field Headed?

Authors:  Aysegul Gunduz; Michael S Okun
Journal:  Curr Neurol Neurosci Rep       Date:  2016-04       Impact factor: 5.081

7.  Chronic antidepressant treatments increase cytochrome b mRNA levels in mouse cerebral cortex.

Authors:  N Y Huang; M Strakhova; R T Layer; P Skolnick
Journal:  J Mol Neurosci       Date:  1997-12       Impact factor: 3.444

8.  The interplay between mitochondrial complex I, dopamine and Sp1 in schizophrenia.

Authors:  Dorit Ben-Shachar
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

Review 9.  Target identification for CNS diseases by transcriptional profiling.

Authors:  C Anthony Altar; Marquis P Vawter; Stephen D Ginsberg
Journal:  Neuropsychopharmacology       Date:  2008-10-15       Impact factor: 7.853

10.  Mitochondrial enzymes in schizophrenia.

Authors:  Parvesh Bubber; Jicheng Tang; Vahram Haroutunian; Hui Xu; Kenneth L Davis; John P Blass; Gary E Gibson
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.